Eli Lilly Surges 10% on Goldman’s Big Target Hike 02/07/26
/
RSS Feed
Eli Lilly Surges 10% on Goldman’s Big Target Hike 02/07/26
Key Stories:
- Shares of Eli Lilly and Company, the pharmaceutical giant, surged approximately 10% after the company delivered its latest earnings report. Goldman Sachs clearly likes what it sees, raising its price recommendation on Eli Lilly stock from $1,145 to a robust $1,260. The firm reiterated its ‘Buy’ rating, citing a strong 25% growth outlook for the company. This move further solidifies Eli Lilly’s position as a top long-term, low-risk stock and indicates significant analyst confidence in its pipeline and market performance, suggesting continued upward momentum for investors. Read more
- Staying within the pharmaceutical sector, Morgan Stanley has adjusted its outlook on Bristol Myers. The firm bumped its price target on Bristol Myers stock up from $37 to $40. However, despite this increase, Morgan Stanley is maintaining an ‘Underweight’ rating on the shares. Analyst Terence Flynn notes that while Bristol Myers’ 2026 revenue and EPS guidance did come in above consensus expectations, this was primarily driven by a higher-than-expected guide for its key drug, Eliquis. Investors will be watching closely to see if the company can broaden its growth drivers beyond this one successful product. Read more
- Shifting gears to the industrial sector, Morgan Stanley also made a notable move on Linde, the global industrial gas and engineering company. The firm elevated its price target on Linde shares from $495 to $530, while reiterating an ‘Overweight’ rating. Morgan Stanley acknowledges that the underlying operating environment remains challenging. However, they anticipate Linde to show improved growth in 2026 compared to the previous year. This optimism is fueled by expectations of fewer headwinds, increased productivity, benefits from new project startups, and potential foreign exchange tailwinds, painting a brighter picture for its future performance. Read more
Keywords: BMY, Bristol Myers, Buy rating, EPS, Eli Lilly, Eliquis, Goldman Sachs, LIN, LLY, Linde, Morgan Stanley, Overweight rating, Underweight rating, earnings, engineering, growth, growth outlook, guidance, industrial gas, macro improvement, pharmaceuticals, price target, revenue, stock jump